Align Technology misses third-quarter revenue estimates on weaker demand for teeth aligners
Shares of the company were down about 3.9% after the bell. The Arizona-based company posted third-quarter revenue of $977.9 million, down 4.9% sequentially, missing estimates of $987.34 million, ...
bovnews6h
Trevi Therapeutics Inc (TRVI) Stock Rated Outperform by Leerink Partners
Notable insider trades include GOOD JENNIFER L, President & CEO at Trevi Therapeutics Inc (TRVI), who sold 40277 shares on Sep 05 ’24, at $3.11 each, totaling $0.13 million. On May 29 ’24, SCIASCIA ...
bovnews12h
Gilead Sciences, Inc. (GILD) Stock Rated Outperform by Leerink Partners
On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $88.16 which represents a slight increase of $1.87 or 2.17% from the prior close of $86.29. The stock opened at ...
AbbVie: Balanced Outlook Amid EPS Adjustments and Pipeline Uncertainties Warrants Hold Rating
David Risinger, an analyst from Leerink Partners, maintained the Hold rating on AbbVie (ABBV – Research Report). The associated price ...
Roivant Sciences (ROIV) Gets a Buy from Leerink Partners
In a report released yesterday, David Risinger from Leerink Partners reiterated a Buy rating on Roivant Sciences (ROIV – Research ...
Mega health care merger may hang on election results, analysts say
Prospects for a potential merger between health insurers Cigna Group and Humana Inc. hinge on the upcoming US presidential election, analysts said.
Fintel on MSN2d
Leerink Partners Upgrades Gilead Sciences (GILD)
Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...
FierceBiotech2d
Vertex posts full pain data ahead of FDA ruling, unpacking combo results, Vicodin miss and stellar safety
Leerink Partners analysts are forecasting annual sales of $866 million in 2026, compared to a consensus of $362 million. The ...
GEN2d
StockWatch: Wave’s RNA Editing Milestone Lifts Korro, ProQR
Two public companies focused on RNA editing therapies, Korro Bio and ProQR, enjoyed impressive stock surges powered by their best-ever one day gains; their share prices lifted by Wave Life Sciences ...
BioSpace2d
5 Sickle Cell Therapies to Watch Following Pfizer’s Oxbryta Exit
In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy, BioSpace looks at five investigational drugs currently making their way through the pipeline.
Natera (NASDAQ:NTRA) Given New $150.00 Price Target at Leerink Partners
Natera (NASDAQ:NTRA – Free Report) had its price objective hoisted by Leerink Partners from $140.00 to $150.00 in a report issued on Thursday, Benzinga reports. Leerink Partners currently has an ...
ETF Daily News4d
908 Devices (NASDAQ:MASS) PT Lowered to $12.00 at Leerink Partners
Shares of NASDAQ MASS opened at $3.59 on Thursday. The firm has a market cap of $123.80 million, a PE ratio of -3.36 and a beta of 0.97. 908 Devices has a 12-month low of $3.24 and a 12-month high of ...